Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

299
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
07/21/2014 07/22/2014 07/23/2014 07/24/2014 07/25/2014 Date
3.56(c) 3.54(c) 3.48(c) 3.34(c) 3.41 Last
163 853 121 930 72 609 297 505 84 294 Volume
+4.71% -0.56% -1.69% -4.02% +2.10% Change
More quotes
Company
Neovacs SA is a biotechnology company. It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer. It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid. The Tumor Necrosis... 
Surperformance© rating of NEOVACS
Trading Rating : Investor Rating :
More about the company
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 0,33 M
EBIT 2014 -8,58 M
Net income 2014 -7,28 M
Debt 2014 3,40 M
Yield 2014 -
Sales 2015 110 M
EBIT 2015 75,0 M
Net income 2015 82,0 M
Finance 2015 76,0 M
Yield 2015 -
PER 2014 -
PER 2015 0,95
EV / Sales 2014 208x
EV / Sales 2015 -0,09x
Capitalization 65,8 M
More Financials
Latest news on NEOVACS
06/19 NEOVACS : Miguel Sieler Head of Neovacs: "We develop a groundbreaking technology..
06/03 NEOVACS : NAMES NATHALIE THOMAS-PUJOL HEAD OF REGULATORY AFFAIRS (DGAP News)
06/03 NEOVACS : names Nathalie Thomas-Pujol as head of Regulatory Affairs
05/20 NEOVACS : to present additional data on SLE treatment at EULAR 2014
05/15 NEOVACS : to present additional data on SLE treatment at EULAR 2014
05/06 NEOVACS : signs strategic sourcing agreement to supply IFNa for phase IIb lupus ..
04/07 NEOVACS : Completes Enrollment for Phase IIB of TNF-Kinoid in Rheumatoid Arthrit..
03/27 NEOVACS : Financial results for 2013
03/27 NEOVACS : Financial Results for 2013
03/12 NEOVACS : announces positive iDSMB review of the phase IIb study of TNF-Kinoid i..
03/12 NEOVACS : Announces Positive iDSMB Review of the Phase IIb Study of TNF-Kinoid i..
02/25 NEOVACS : Strengthens Its Expertise in Four Therapeutic Areas
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
NEOVACS : Income Statement Evolution
More Financials
EPS Revisions
NEOVACS : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF